Back to resultsCorneal Thinning During Topical Bevacizumab Therapy
Primary Purpose
Corneal Neovascularization
Status
Withdrawn
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
bevacizumab (Avastin)
Sponsored by
About this trial
This is an interventional basic science trial for Corneal Neovascularization
Eligibility Criteria
Inclusion Criteria:
- clinical diagnosis of corneal neovascularization
- must be able to apply eyedrop
Exclusion Criteria:
- have active keratitis
Sites / Locations
- Severance hospital
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00515684
Brief Title
Corneal Thinning During Topical Bevacizumab Therapy
Study Type
Interventional
2. Study Status
Record Verification Date
April 2015
Overall Recruitment Status
Withdrawn
Why Stopped
Side effect can increase the risk of the research
Study Start Date
May 2007 (undefined)
Primary Completion Date
December 2008 (Actual)
Study Completion Date
December 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Yonsei University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine whether topical bevacizumab is safe or not when used in corneal neovascularization for long term period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Corneal Neovascularization
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
bevacizumab (Avastin)
10. Eligibility
Sex
All
Eligibility Criteria
Inclusion Criteria:
clinical diagnosis of corneal neovascularization
must be able to apply eyedrop
Exclusion Criteria:
have active keratitis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sang Woo Kim, M.D.
Organizational Affiliation
Severance hospital, Seoul , Korea
Official's Role
Principal Investigator
Facility Information:
Facility Name
Severance hospital
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Corneal Thinning During Topical Bevacizumab Therapy
We'll reach out to this number within 24 hrs